기관지폐이형성증(BPD) : 세계 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(주요 32 시장) - 2025-2035년

Global Bronchopulmonary Dysplasia (BPD) Market Outlook

Thelansis's "Global Bronchopulmonary Dysplasia (BPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchopulmonary Dysplasia treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Bronchopulmonary Dysplasia (BPD) Overview

Bronchopulmonary dysplasia (BPD) is the most common chronic respiratory complication of prematurity, primarily affecting extremely low birth weight (ELBW) infants born before 28 weeks of gestation. In the modern "post-surfactant" era, BPD is characterized by arrested alveolar and pulmonary vascular development, resulting in structurally simplified lungs with fewer, larger alveoli and impaired gas exchange capacity.

The pathogenesis is multifactorial, driven by the interplay of premature lung immaturity, inflammation, oxygen toxicity, and ventilator-induced injury (volutrauma and barotrauma). These insults disrupt normal lung development and initiate long-term pulmonary dysfunction.

Clinically, BPD is defined by the requirement for supplemental oxygen or respiratory support at 36 weeks post-menstrual age, with severity linked to duration and intensity of support. Survivors face a high risk of chronic respiratory morbidity, including pulmonary hypertension, recurrent wheezing, and long-term neurodevelopmental impairment.

Management remains largely supportive and preventive, focusing on minimizing lung injury through early use of non-invasive ventilation (e.g., CPAP), optimized oxygen targeting, surfactant therapy, caffeine citrate for apnea, and careful nutritional support. Corticosteroids may be used selectively to reduce inflammation and facilitate weaning from respiratory support, though their use requires careful risk-benefit assessment.

Despite advances in neonatal care, no definitive curative therapies exist, and outcomes are highly dependent on early intervention strategies, highlighting a significant unmet need for disease-modifying treatments.

Key Highlights

• In Germany, incident BPD cases are projected to increase from 2,851 to 3,057, reflecting a gradual rise linked to improved survival of preterm infants.
• Gender distribution shows a higher burden in males, with 55% male vs 45% female (2025).
• BPD remains a leading cause of long-term respiratory and neurodevelopmental complications in preterm infants.
• Lack of curative therapies underscores reliance on preventive and supportive care strategies.
• Increasing survival of extremely preterm infants is expected to expand the at-risk population, sustaining disease burden.

Market Overview

• The Germany BPD market is projected to grow from $15M to $72M, indicating strong expansion from a low base.
• Market growth is driven by:
• Increased survival rates of extremely preterm infants
• Adoption of advanced neonatal care and supportive therapies
• Despite a relatively small patient population, market value is supported by intensive care requirements and prolonged treatment duration.
• Emerging research in regenerative therapies, stem cell approaches, and anti-inflammatory agents is expected to shape future market potential.
• Future growth will depend on development of disease-modifying interventions targeting lung development and inflammation.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Airway Therapeutics, Inc.
• Medipost Co Ltd.
• OHB Neonatology Ltd

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)